Celularity Inc. Secures Over $10 Million in Debt Financing to Support Growth and Target Positive Cash Flow by Q1 2027

Celularity Inc. (NASDAQ: CELU) announced on 24 September 2026 that it has closed an initial financing of more than $10 million as part of a larger $28 million recapitalization effort. The funds were raised through a debt instrument and are intended to accelerate the company’s growth initiatives following notable operating improvements.

Key Points of the Financing

  • Amount raised: Over $10 million in debt financing.
  • Purpose: To support development and commercialization of off‑the‑shelf placental‑derived allogeneic cell therapies, including natural killer (NK) cells, genetically modified NK cells, chimeric antigen receptor (CAR) T‑cells, and mesenchymal‑like adherent stromal cells (ASCs).
  • Strategic goal: Achieve a positive cash‑flow position by Q1 2027.

Implications for the Company

The infusion of capital strengthens Celularity’s balance sheet and provides the liquidity needed to advance its clinical programs across multiple disease areas, such as cancer, infectious diseases, and degenerative conditions. The company’s recent operating improvements, coupled with this financial backing, are expected to enhance its capacity to pursue research and development milestones and to scale production and supply chains.

Market Context

  • Current share price (22 Sept 2026): $1.15.
  • 52‑week high: $2.55 (26 Aug 2026).
  • 52‑week low: $0.56 (29 Jun 2026).
  • Market capitalization: $33,287,854.
  • Price‑to‑earnings ratio: –0.34 (indicative of current operating losses).

The financing reflects investor confidence in Celularity’s therapeutic platform and its potential to generate sustainable revenue streams in the medium term.

Celularity’s official website, www.celularity.com , provides additional details on its product pipeline, clinical progress, and corporate strategy.